Clinical trials: Prostatic Disease
Benign Prostatic Hyperplasia
Prospective Controlled Randomized Study of PAE vs TURP for BPH Treatment.
The purpose of this prospective randomized controlled study is to compare the improvement of symptoms from benign prostatic hyperplasia (BPH) and the improvement of QoL, in patients undergoing prostatic artery embolization (PAE)…
- Trial name
- NCT02566551
- Testing
- PAE, Gelatin microspheres, TURP
- Where
- Spain
- Sponsor
- Group of Research in Minimally Invasive Techniques
Prostatic Neoplasms, Prostate Cancer
18F-DCFBC PET/CT in Prostate Cancer
Background: Prostate cancer is the second leading cause of cancer deaths in American men. A chemical called a radiotracer helps doctors get images of this type of cancer.
- Trial name
- NCT02190279
- Testing
- 18F DCFBC, Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Ketoconazole, Hydrocortisone and Dutasteride in Asymptomatic Hormone Refractory Prostate Cancer
The combination of ketaconazole and hydrocortisone is commonly used for the treatment of prostate cancer. The purpose of this study is to determine if the addition of a drug called dutasteride to this approved combination will…
- Trial name
- KHAD (NCT00673127)
- Testing
- Ketoconazole, Hydrocortisone and Dutasteride
- Where
- 7 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- Beth Israel Deaconess Medical Center
Cellular Diagnosis, Prostate Cancer
ClariCore System Used in Transrectal Ultrasound Guided Prostate Biopsy for Real-Time Tissue Evaluation
The purpose of this study is to demonstrate the effectiveness and safety of the ClariCore System in obtaining prostate biopsies with device feedback that provides real-time tissue classification.
- Trial name
- SCORE (NCT03504761)
- Testing
- ClariCore Optical Biopsy System
- Where
- 6 sites in United States
- Volunteers
- 325 people
- Sponsor
- Precision Biopsy, Inc.
Prostate Cancer, Kidney Cancer
DS Titanium Ligation Clip in Urology (Prostatectomy and Nephrectomy)
Prospective, monocentric, single arm, observational PMCF - Study on the Performance and Safety of Double-Shank Titanium Ligation Clip in Urology (Prostatectomy and Nephrectomy)
- Conditions
- Prostate Cancer, Kidney Cancer, Congenital Abnormality of Kidney, Nephrolithiasis
- Trial name
- DOSTILCU (NCT04869462)
- Where
- Germany
- Volunteers
- 67 people
- Sponsor
- Aesculap AG
Prostate Cancer
Transperineal Versus Transrectal Prostate Biopsy
Background: Prostate biopsies are essential to diagnose prostate cancer (PCa). Transrectal prostate biopsies (TR-PB) are commonly performed, however disadvantages include the requirement of antibiotic prophylaxis (AP) and higher…
- Trial name
- NCT06027203
- Testing
- prostate biopsy
- Where
- Netherlands
- Volunteers
- 923 people
- Sponsor
- Maastricht University Medical Center
Prostate Cancer
A Phase I/II Study of HE3235 in Patients With Prostate Cancer
This is a phase I/II, open-label, dose escalation study of HE3235 administered orally to patients with advanced prostate cancer who have failed hormone therapy and at least one taxane based chemotherapy regimen.
- Trial name
- NCT00716794
- Testing
- HE3235
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Harbor Therapeutics
Cancer of the Prostate
Maintaining Suppression of Testosterone With Transdermal Estradiol Gel
The objective of this clinical study is to evaluate the safety and efficacy of three different doses of BHR-200 (0.36% transdermal estradiol gel) compared to placebo for the maintenance of testosterone (T) suppression in men with…
- Trial name
- MASTERS (NCT02349386)
- Testing
- BHR-200 (0.36% transdermal 17β-estradiol gel)
- Where
- 12 sites in United States
- Volunteers
- 34 people
- Sponsor
- BHR Pharma, LLC
Prostate Cancer, Lower Urinary Tract Symptoms
HoLEP Prior to Radiation Therapy for Patients With LUTS/Retention and Concurrent Prostate Cancer
To determine if holmium laser enucleation of the prostate (HoLEP) for the treatment of lower urinary tract symptoms (LUTS) and/or urinary retention alters the treatment course for patients concurrently diagnosed with prostate…
- Trial name
- HOLEP-RTPC (NCT03802851)
- Testing
- Holmium Laser Enucleation of Prostate (HoLEP)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Kansas Medical Center
Prostate Cancer, Metastatic Prostate Cancer
Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms
Local cytoreductive treatments for men with newly diagnosed metastatic prostate cancer in addition to standard of care treatment
- Trial name
- IP2-ATLANTA (NCT03763253)
- Testing
- Standard of Care, Minimally Invasive Ablative Therapy (MIAT), Radical Therapy (Prostatectomy or Radiotherapy)
- Where
- 21 sites in United Kingdom
- Volunteers
- 433 people
- Sponsor
- Imperial College London
Urologic Diseases, Prostate Obstruction
Laser Outcomes Associated With (Holmium Laser Enucleation of the Prostate) HoLEP Procedures
The primary aim is to assess the impact of laser setting frequency and wattage during holmium laser enucleation of the prostate.
- Trial name
- NCT06531473
- Testing
- HoLEP
- Where
- United States
- Volunteers
- 278 people
- Sponsor
- Northwestern University
Prostate Cancer, Benign Prostatic Hyperplasia
BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)
This is a pilot study examining biological endpoints in men with localized prostate cancer who are scheduled to have radical prostatectomies and men with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS)…
- Conditions
- Prostate Cancer, Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)
- Trial name
- NCT01520441
- Testing
- BOTOX
- Where
- United States
- Sponsor
- The University of Texas Health Science Center, Houston
Prostate Cancer
Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer
The primary objective of the study is to determine a recommended phase II dose (RP2D). The secondary objective of the study are: 1.
- Trial name
- Tax-Sam (NCT00559429)
- Testing
- Docetaxel
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer
This phase II trial studies how well surgery and radiation therapy work in treating patients with prostate cancer that has come back or spread to other parts of the body.
- Conditions
- Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Oligometastasis
- Trial name
- SOAR (NCT03796767)
- Testing
- Hypofractionated Radiation Therapy, Intensity-Modulated Radiation Therapy, Metastasectomy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Utah
Prostate Cancer
Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer
The goal of this clinical study is to determine the safety and efficacy of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with…
- Trial name
- NCT02130700
- Testing
- VT-464: given orally twice daily in 28-day cycles, VT-464: given orally once daily in 28-day cycles
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Innocrin Pharmaceutical
Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
This is a single-center, open-label, study of Prostate-Specific Membrane Antigen (PSMA)-targeted radionuclide therapy with 177Lu-PSMA-617 in combination with pembrolizumab in participants with metastatic castrate-resistant…
- Conditions
- Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Carcinoma
- Trial name
- NCT05766371
- Testing
- Pembrolizumab, 177Lu-PSMA-617
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of California, San Francisco
NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
This is a Phase 1b, 2-part, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity…
- Conditions
- NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage
- Trial name
- BActinium-2 (NCT07887971)
- Testing
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Where
- 2 sites in United States
- Volunteers
- 152 people
- Sponsor
- Aktis Oncology, Inc.
Metastatic Hormone-Sensitive Prostate Cancer
Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer
This multicenter, prospective, cohort study enrolled patients with metastatic hormone-sensitive prostate cancer who had been treated with other novel endocrine or systemic regimens (excluding patients treated with pre-order…
- Trial name
- RASTOM (NCT06134271)
- Testing
- Rezvilutamide, Rezvilutamide plus abiraterone, Continue previous treatment
- Volunteers
- 160 people
- Sponsor
- Jianbin Bi
CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
This is a study of CDX-1127, a therapy that targets the immune system and may act to promote anti-cancer effects. The study enrolls patients with hematologic cancers (certain leukemias and lymphomas), as well as patients with…
- Conditions
- CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone B Cell Lymphoma)
- Trial name
- NCT01460134
- Testing
- CDX-1127
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- Celldex Therapeutics
Prostate Cancer, Recurrent Prostate Cancer
Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer
This is a multi-center clinical study enrolling up to 12 participants . The primary objective of the study is to evaluate the safety of Alpha DaRT for the treatment of locally recurrent prostate cancer .
- Conditions
- Prostate Cancer, Recurrent Prostate Cancer, Locally Recurrent Prostate Cancer
- Trial name
- NCT07290998
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Volunteers
- 12 people
- Sponsor
- Alpha Tau Medical LTD.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.